Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pulmonx Corporation

https://pulmonx.com/

Latest From Pulmonx Corporation

Financing: Q3 Roundup Shows Fall In Device Company Activity But A Rise In IVDs

During the third quarter, device company fundraising totaled $3.3bn; while in vitro diagnostic firms and research tools players raised $3.4bn.

Companies Financing

Finance Watch: Five More Biopharma IPOs In The US Raise $624.7m

Public Company Edition: Outside the US, Zai Lab raised more in its recent Hong Kong initial public offering – $766.4m – than PMV, Prelude, Taysha, Graybug and Greenwich combined. Also, Gilead priced debt to fund its $21bn Immunomedics buy and ADC Therapeutics raised $204m.

Financing Growth

Pulmonx Picks Up $86M IPO Plans After COVID-19 Disruption

The company originally filed to list on the NASDAQ in February but withdrew as the pandemic hit.

Respiratory Commercial

Pulmonx's FDA Nod: First To US Market With Endobronchial Valve System

Pulmonx announced US FDA approval of its Zephyr endobronchial valve system for treating severe emphysema patients. This makes it the first minimally invasive device to be approved in the US for treating severe emphysema, a severe form of chronic obstructive pulmonary disease.

Approvals Respiratory
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Implantable Devices
    • Diagnostic Imaging Equipment & Supplies
      • Digital Imaging
UsernamePublicRestriction

Register